

REMARKS/ARGUMENTS

Petition is hereby made under the provisions of 37 CFR 1.136(a) for an extension of three months of the period for response to the Office Action. The prescribed fee should be charged to our Deposit Account No. 19-2253 and our Deposit Account Order Form is enclosed.

The Examiner made the restriction requirement final and withdrew claims 3 and 8 from consideration.

The Examiner rejected claims 1, 2, 4 to 7 and 9 to 23 under 35 USC 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

In this regard, claims 21 to 23 directed to a method of protecting a host have been deleted without prejudice. In addition, claim 1 has been amended to delete reference to protection. It is submitted that the claims now present in the application are fully enabled.

Applicants claim an immunogenic composition comprising two vectors and a pharmaceutically-acceptable carrier. The first of these vectors comprises a first nucleotide sequence encoding a major outer membrane protein (MOMP) of a strain of *Chlamydia* and a first promoter operatively coupled to the first nucleotide sequence for expression of said MOMP in the host. The second of the vectors comprises a second nucleotide sequence encoding a 76 kDa protein of a strain of *Chlamydia* and a second promoter sequence operatively coupled to said second nucleotide sequence for expression of 76 kDa protein in the host. The manners of provision of the vectors and of the immunogenic composition are clearly described in the specification.

Applicants data shows that such composition is immunogenic and, indeed, in mice provides protection against intranasal challenge by *C. pneumoniae*. Thus, the claimed immunogenic composition has been shown to provide an immune response.

The Anderson reference cited by the Examiner is a review article comprising human gene therapy. It is noted that applicants do not claim a therapeutic procedure, claims 21 to 23 having been deleted. The McCluskie et al